The Federal Circuit affirmed a ruling that Wyeth’s patents for treating drug-resistant lung cancer were invalid for lack of enablement, wiping out a $107.5 million jury verdict against AstraZeneca. The precedential decision found the specifications’ lab data and broad dosage ranges did not teach a workable patient dosing regimen.

Read more: https://www.cafc.uscourts.gov/opinions-orders/24-2325.OPINION.7-9-2026_2720804.pdf